Literature DB >> 24362488

Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive.

Maribel Reyes1, Patrick Brossard, Didier Chassard, Matthias Hoch, Jasper Dingemanse.   

Abstract

PURPOSE: To determine the effects of steady-state concentrations of the selective S1P1 receptor modulator ponesimod on the pharmacokinetics (PK) of a single dose of a combined oral contraceptive, containing 1 mg norethisterone (NET) and 35 μg ethinyl estradiol (EE) and to investigate the effects on heart rate at different ponesimod doses within an up-titration regimen prior to co-administration of the contraceptive.
METHODS: Twenty-two healthy women (age: 29-60 years) received twice a single oral dose of the combined oral contraceptive, alone or in combination with multiple doses of 40 mg ponesimod attained by an up-titration regimen. Heart rate (HR) effects were assessed on the first day of each up-titration level. PK parameters of NET and EE were determined by non-compartmental analysis.
RESULTS: Geometric mean ratios (ponesimod and contraceptive / contraceptive alone) of Cmax and AUC0-24 of NET were 0.87 (90 % CI: 0.80, 0.94) and 0.84 (90 % CI: 0.76, 0.93), respectively. Geometric mean ratios of Cmax and AUC0-24 of EE were 0.94 (90 % CI: 0.86, 1.03) and 0.95 (90 % CI: 0.89, 1.01), respectively. The maximum mean HR reduction after the first dose of 10 mg ponesimod was 12.4 bpm (SD ± 6.2) at 2.5 h post-dose. On Day 4 (first dose of 20 mg) and Day 7 (first dose of 40 mg) the maximum mean HR reduction was 4.3 bpm (SD ± 5.7) and 1.4 (SD ± 6.4), respectively, at 2.5 h post-dose compared to baseline.
CONCLUSION: No clinically relevant PK interactions between ponesimod and the combined oral contraceptive were observed, therefore, efficacy of hormonal contraceptives is not expected to be affected by concomitant administration of ponesimod. The up-titration regimen showed that HR reductions are diminished upon repeated ponesimod administration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362488     DOI: 10.1007/s00228-013-1625-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.

Authors:  D Ouellet; A Hsu; J Qian; C S Locke; C J Eason; J H Cavanaugh; J M Leonard; G R Granneman
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

2.  The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

Authors:  Luca Piali; Sylvie Froidevaux; Patrick Hess; Oliver Nayler; Martin H Bolli; Eva Schlosser; Christopher Kohl; Beat Steiner; Martine Clozel
Journal:  J Pharmacol Exp Ther       Date:  2011-02-23       Impact factor: 4.030

3.  Evaluation of interaction between fluconazole and an oral contraceptive in healthy women.

Authors:  J Hilbert; M Messig; O Kuye; H Friedman
Journal:  Obstet Gynecol       Date:  2001-08       Impact factor: 7.661

4.  Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.

Authors:  W E Rosenfeld; D R Doose; S A Walker; R K Nayak
Journal:  Epilepsia       Date:  1997-03       Impact factor: 5.864

Review 5.  Drug interactions between antiretrovirals and hormonal contraceptives.

Authors:  Alice Tseng; Cara Hills-Nieminen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-02-21       Impact factor: 4.481

6.  The interaction between St John's wort and an oral contraceptive.

Authors:  Stephen D Hall; Zaiqi Wang; Shiew-Mei Huang; Mitchell A Hamman; Nina Vasavada; Adegboyega Q Adigun; Janna K Hilligoss; Margaret Miller; J Christopher Gorski
Journal:  Clin Pharmacol Ther       Date:  2003-12       Impact factor: 6.875

7.  Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.

Authors:  Vanitha J Sekar; Eric Lefebvre; Sabrina Spinosa Guzman; Elise Felicione; Martine De Pauw; Tony Vangeneugden; Richard M W Hoetelmans
Journal:  Antivir Ther       Date:  2008

8.  Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.

Authors:  Patrick Brossard; Hartmut Derendorf; Jian Xu; Haidar Maatouk; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

9.  B-cell targeting agents in the treatment of multiple sclerosis.

Authors:  Tiffany J Braley; Benjamin M Segal
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 10.  Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management.

Authors:  Caryn Dutton; Nancy Foldvary-Schaefer
Journal:  Int Rev Neurobiol       Date:  2008       Impact factor: 3.230

View more
  5 in total

1.  Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies.

Authors:  Dominik Lott; Thorsten Lehr; Jasper Dingemanse; Andreas Krause
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

2.  Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.

Authors:  Andreas Krause; Patrick Brossard; Daniele D'Ambrosio; Jasper Dingemanse
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-15       Impact factor: 2.745

Review 3.  Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.

Authors:  Daniele D'Ambrosio; Mark S Freedman; Joerg Prinz
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

4.  Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.

Authors:  Pierre-Eric Juif; Matthias Hoch; Daniele D'Ambrosio; Jasper Dingemanse
Journal:  Drugs R D       Date:  2015-06

5.  Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects.

Authors:  Pierre-Eric Juif; Daniela Baldoni; Maribel Reyes; Darren Wilbraham; Salvatore Febbraro; Andrea Vaclavkova; Matthias Hoch; Jasper Dingemanse
Journal:  Int J Mol Sci       Date:  2017-12-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.